# A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma

> **NCT01800071** · PHASE1 · COMPLETED · sponsor: **Cancer Research UK** · enrollment: 22 (actual)

## Conditions studied

- Nasopharyngeal Cancer
- Epstein Barr Virus Infections

## Interventions

- **DRUG:** MVA-EBNA1/LMP2 vaccine

## Key facts

- **NCT ID:** NCT01800071
- **Lead sponsor:** Cancer Research UK
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2017-03-10
- **Final completion:** 2017-03-10
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2018-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01800071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01800071, "A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01800071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*